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Background: Fatigue is a common and debilitating symptom of Multiple Sclerosis (MS); 
however, it is unknown what constitutes a clinically significant change in fatigue. 
Establishing the minimally important difference (MID) of fatigue outcome measures can 
inform the interpretation of changes in fatigue by estimating the level of change that is 
considered clinically relevant.  
Aim: Determine the MID for the Fatigue Severity Scale (FSS) and Modified Fatigue Impact 
Scale (MFIS) in people with MS. 
Methods: This cross-sectional study collected information on self-reported fatigue (FSS and 
MFIS) and quality of life (EQ-5D and MS Impact Scale 29) through an online survey. 
Anchor-based methods were used to estimate MID, and ordinal logistic regression models 
were used to determine the difference in fatigue that would predict a significant effect on 
quality of life.  
Results: 365 people with MS (81.9% female, 69.3% relapsing-remitting MS, mean age 
46.2±11.6 years, mean time since diagnosis 9.6±8.7 years) responded to the survey. MID 
estimates for the FSS and MFIS ranged from 0.45-0.88 and 3.86-8.11 respectively, 
accounting for 6.4-12.6% of maximum FSS score and 4.6-9.7% of maximum MFIS score.  
Conclusions: MID estimates derived from this study indicate that a difference of at least 0.45 
points on the FSS or 4 points on the MFIS constitutes a clinically significant difference in 
fatigue. Therefore, these estimates represent a threshold value which can be used to interpret 
changes in the FSS and MFIS over time or in response to an intervention.  
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Fatigue is a complex symptom of Multiple Sclerosis (MS) that is reported in 70% of the 
population (Lerdal et al., 2007; Hadjimichael et al., 2008; Rooney et al., 2019), and is often 
perceived as the most debilitating symptom which significantly impacts upon quality of life 
(QoL) (Bakshi, 2003). Fatigue may be described as exhaustion, a lack of energy, or 
overwhelming tiredness which can occur at rest (Mills & Young, 2008), and is commonly 
defined as “a subjective lack of physical and/or mental energy that is perceived by the 
individual or caregiver to interfere with usual and desired activities” (Multiple Sclerosis 
Council for Clinical Practice Guidelines, 1998). Due to the subjective nature of fatigue, 
patient reported outcome measures (PROMs) are commonly used to assess the severity and 
impact of fatigue, and two of the most frequently used in studies involving people with MS 
are the Fatigue Severity Scale (FSS) and the Modified Fatigue Impact Scale (MFIS) 
(Blikman et al., 2013; Heine et al., 2015; van den Akker et al., 2016).  
 
Interpreting changes in PROMs is important when evaluating the effectiveness of 
interventions, and it is recognised that conventional statistical analysis provides little 
information regarding the clinical significance of changes observed following an intervention 
(Goodman, 1999). However, the interpretation of meaningful changes in fatigue can be 
enhanced by establishing the minimally important difference (MID) for fatigue PROMs 
(Revicki et al., 2006). MID, which is defined as “the smallest difference in the outcome of 
interest which patients perceive as beneficial” (Jaeschke et al., 1989), is a threshold value 
used to interpret whether a change in an outcome is important from the patient’s perspective 
(Guyatt et al., 2002). MID can be determined using anchor-based or distribution-based 
methods – the details of which are reported elsewhere (Beaton et al., 2002; Guyatt et al., 
2002; Copay et al., 2007; Revicki et al., 2008). Briefly, distribution-based methods make use 
of the statistical characteristics of the distribution of scores – standard deviation and standard 
error of measurement – to determine the MID, but are criticised for failing to convey the 
patient’s perspective when determining what constitutes a meaningful difference (Revicki et 
al., 2008). Alternatively, anchor-based methods use external indicators that are often patient-
reported to determine the level of change in the PROM of interest that results in a significant 
difference in the anchor measurement (Revicki et al., 2008). As anchor-based methods 
usually use the patient’s perspective when interpreting change in PROMs, this method is 
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thought to generate more meaningful estimates of MID in comparison to distribution-based 
methods.  
 
Despite the prevalence and impact of fatigue in people with MS, few studies have estimated 
MID values for fatigue outcome measures in this population (Nordin et al., 2016), with only 
one study estimating MID for the FSS in a relapsing-remitting MS population (Robinson et 
al., 2009) and another estimating MID of the Fatigue Impact Scale (Rendas-Baum et al., 
2010). Consequently, it is currently unclear what constitutes a meaningful change in fatigue 
in people with MS. This limits the interpretation of treatment effectiveness when evaluating 
fatigue management interventions, as it is not possible to determine whether interventions 
have a clinically significant effect on fatigue. In addition to evaluating changes in fatigue, 
MID estimates are important for the planning of clinical trials that are adequately powered to 
detect changes in fatigue through informing sample sizes calculations. Therefore, this study 
aims to determine the MID for the FSS and MFIS in a MS population using anchor-based 
methods.  
 
2 Methods  
2.1 Design and participant recruitment 
This study used cross-sectional data collected through an online survey that was designed 
using RedCap software v6.15. The survey was open-access and made available for one month 
between 30 May-30 June 2018, and potential participants were recruited through information  
shared online by international MS charities and organisations based in the UK, USA, and 
Australia. Eligible participants were required to confirm that they had a medical diagnosis of 
MS, were aged 18 years or older, and were asked to provide consent before accessing the 
main survey questions. Data collected through the survey included self-reported demographic 
information, and a series of PROMs which included measures of fatigue (FSS and MFIS), 
MS impact, and QoL. Both MS impact and QoL were chosen as anchors in this study due to 
their association with fatigue (Janardhan et al., 2002; Lerdal et al., 2007; Mills & Young, 
2011), and both measures represent multidimensional global ratings of health and function 
that would enable quantification of meaningful differences in fatigue. In addition, participants 
5 
 
were required to complete the Patient Determined Disease Steps (PDDS), which is a valid 
and reliable self-reported measure of disability in MS populations (Hohol et al., 1995; 
Schwartz et al., 1999). The survey took approximately 30-40 minutes to complete, and 
participants were allowed to save responses and return to the survey at a later time. Ethical 
approval for this study was obtained from Glasgow Caledonian University School of Health 
and Life Sciences Ethics Committee.  
 
2.2 Outcome measures 
2.2.1 Fatigue 
Fatigue was assessed using the FSS and MFIS. The FSS is a nine-item unidimensional 
questionnaire which measures the severity of fatigue symptoms on a seven-point ordinal scale 
(maximum score of seven) (Krupp et al., 1989), whereas the MFIS is a 21-item 
multidimensional questionnaire that measures the physical, cognitive, and psychosocial 
impact of fatigue using a five-point ordinal scale (maximum total score of 84) (Multiple 
Sclerosis Council for Clinical Practice Guidelines, 1998). Higher scores recorded on both 
scales indicate greater impact/severity of fatigue symptoms. The FSS and MFIS are reliable 
measures of fatigue, and both scales have strong internal consistency and high precision in 
MS populations (Flachenecker et al., 2002; Amtmann et al., 2012; Learmonth et al., 2013).  
 
2.2.2 Quality of life 
The EQ-5D-3L was used to measure QoL. The EQ-5D-3L requires participants to rate their 
health over five domains – mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression – using a 3 point ordinal scale. Participant response over the five health 
domains generates a health index with a maximum score of 1 indicating ‘full health’ 
(EuroQol Group, 1990). The UK value set was used to generate the weighted health index 




2.2.3 MS impact 
The MS Impact Scale-29 (MSIS-29) version one was used to measure MS impact. The 
MSIS-29 assesses the physical and psychological impact of MS in response to 29 items, 
producing physical and psychological subscale scores which range between 20-100 and 9-45 
respectively (Hobart et al., 2001). The MSIS-29 demonstrates strong validity and reliability 
in MS populations (Hobart et al., 2001; McGuigan et al., 2004; Gray et al., 2009).  
 
2.3 Data analysis  
All participants who provided complete questionnaire responses were included in the data 
analysis. Demographic characteristics and questionnaire responses of study participants were 
reported as mean values as data were normally distributed according to the Shapiro-Wilk 
statistic. In order to derive MID values for the FSS and MFIS, ordinal logistic regression 
models (specifically proportional odds models) were used to predict the difference in fatigue 
PROM scores that would result in a change in each MSIS-29 and EQ-5D-3L response item. 
Therefore, 34 response items (29 from MSIS-29 and 5 from EQ-5D-3L) were considered as 
potential anchor variables for each analysis. All data analysis was performed using IBM 
SPSS v23 (IBM Corporation, Armonk, NY, USA). 
 
2.3.1 Anchor variable selection  
To assess the viability of each anchor variable, Spearman correlation coefficients were 
calculated to determine the strength of association between potential anchors and fatigue 
(FSS and MFIS scores), with correlation coefficients ≥0.3 being used to select anchor 
variables (Revicki et al., 2008). In addition, the proportional odds assumption was assessed 
using the probability values derived from the test of parallel lines to determine whether the 
cumulative odds ratio was consistent between each response category of the anchor variable. 





2.3.2 Determining minimally important difference  
MID scores were derived using ordinal logistic regression methods recommended by Angst et 
al. (2017) and previously used by Rendas-Baum et al. (2010) in a similar cross-sectional 
study of people with MS. Initially, proportional odds models were used to predict the effects 
of the independent variables – FSS and MFIS – on each dependent anchor variable that 
fulfilled the selection criteria (Supplementary Table 1). According to the proportional odds 
model, the odds ratio associated with moving between ordinal response categories on the 
dependent anchor variable (that is either worsened or improved QoL/MS impact), is 
proportional to change in the independent variable. Therefore, using the coefficients (β) 
generated from each proportional odds model, MID was estimated based on the smallest 
difference in FSS/MFIS scores that predicted a 1.5 odds of moving between response 
categories for each anchor variable using the following formula: x=ln(1.5)/β (where x is the 
difference in FSS/MFIS scores, thus representing the MID). In line with the methods 
described by Rendas-Baum et al. (2010), an odds ratio of 1.5 was selected as this corresponds 
to a standardised difference of 2.54 and a small effect size (Cohen, 1992; Tritchler, 1995). 
Therefore, MID scores translate to the difference in fatigue outcome that would predict at 
least a small effect on QoL and MS impact.  
 
3 Results 
3.1 Demographic data 
Of the 498 people who agreed to take part in the survey, 365 (73%) provided sufficient data 
to be included in this analysis. Participants were mostly female (81.9%), had a relapsing-
remitting form of MS (69.3%), and had a mean age of 46.2 ± 11.6 years and time since 
diagnosis of 9.6 ± 8.7 years (Table 1). In addition, the mean PDDS score was 3.1 ± 2.3 
indicating that participants mostly reported mild-moderate levels of disability. Descriptive 
statistics for each of the possible 34 anchor variables are provided in Table 2.  
 




Table 2 near here 
 
3.2 Anchor variable selection  
Overall, 26 and 28 variables met the selection criteria and were regarded as eligible anchor 
variables for determining the MID of the FSS and MFIS respectively. Of the eight variables 
excluded from the FSS analysis, three were excluded as Spearman correlation coefficients 
were found to be <0.3 (EQ-5D item 4 = 0.296; EQ-5D item 5 = 0.230; MSIS-29 item 24 = 
0.293) (Table 3). The remaining variables were excluded following the test of parallel lines, 






















= 17.825, p<0.001) items of the MSIS-29. For the MFIS analysis, all 34 
potential anchor variables demonstrated an association with MFIS scores (rs≥0.3); however, 
six variables were excluded due to violation of the proportional odds assumption including 
the 5
th
 item of the EQ-5D (χ
2 





















12.244, p = 0.007) items of the MSIS-29.   
 
Table 3 near here 
 
3.3 Minimally important difference of the Fatigue Severity Scale and 
Modified Fatigue Impact Scale 
Estimates of MID for the FSS ranged between 0.45-0.88 (6.4-12.6% of maximum FSS score), 
and the mean MID estimate from the 26 anchor variables was 0.68 ± 0.12 (Figure 1). The 
anchor variable with the smallest MID estimate (0.45) was MSIS-29 item 13 which asked 
participants: “how much has your MS limited your social and leisure activities at home”. 
Similarly, items 14 and 19 of the MSIS-29, which related to activity limitations, were also 
sensitive to differences in fatigue, with MID estimates of 0.52 and 0.50 respectively. The 
least sensitive anchor variables were MSIS-29 items 9 (MID = 0.88) and 22 (MID = 0.87), 
which asked participants how much they have been affected by “tremor of your arms and 




For the MFIS, estimates of MID ranged from 3.86-8.11 (4.6-9.7% of maximum MFIS score), 
and the mean MID estimate from the 28 anchor variables was 6.25 ± 1.13 (Figure 1). Similar 
to the FSS, smaller MID estimates were derived from anchor variables that were related to 
activity limitations such as MSIS-29 items 13 “how much has your MS limited your social 
and leisure activities at home” (MID = 4.94) and 14 “how much has your MS resulted in you 
being stuck at home more than you would like to be” (MID = 4.94) and 18 “how much has 
your MS resulted in you taking longer to do things?” (MID = 4.77). However, the smallest 
MID estimate for the MFIS was derived from MSIS-29 item 23: “how much have you been 
bothered by feeling mentally fatigued” (MID = 3.86). The least sensitive anchor variables 
were EQ-5D item 1 (mobility) and item 2 (self-care) with MID estimates of 8.11 and 7.80 
respectively.  
 
Figure 1 near here 
 
4 Discussion  
This study estimated that the MID of the FSS ranged between 0.45-0.88, meaning that a 
difference of 6.4-12.6% in the maximum FSS score would predict at least a small effect on 
QoL and MS impact. In addition, the MID of the MFIS was estimated to range from 3.86-
8.11, accounting for 4.6-9.7% of the maximum MFIS score. Therefore, these findings suggest 
that a threshold value of at least 0.45 points for the FSS and 4 points for the MFIS constitutes 
a clinically significant difference in outcome measure scores. Accordingly, the MID 
estimates reported in this study can be used to interpret changes in the FSS and MFIS, and 
evaluate the effectiveness of interventions in managing fatigue.  
 
Importantly, this is the first study to estimate MID for the MFIS in a MS population, and 
although another study has estimated MID for the FSS in people with relapsing-remitting MS 
(Robinson et al., 2009), the present study has a larger sample size (n= 365 vs. 249), includes 
both progressive and relapsing-remitting MS types, and used a greater number of anchor 
variables. The findings of the present study are similar to those of Robinson et al. (2009) as 
10 
 
MID for the FSS was reported to range between 0.5 and 1.1, accounting for 7.1-15.7% of 
maximum FSS score. In addition, although Rendas-Baum et al. (2010) calculated MID for the 
Fatigue Impact Scale (FIS), the MID estimate of 5.6-15.0% of maximum FIS score is similar 
to the results of the present study for the FSS, but is larger than the estimated value for the 
MFIS. While another study by Learmonth et al. (2013) reported that significantly larger 
differences in FSS (38%) and MFIS (49%) scores constitute a clinically significant change, 
these estimates refer to the minimal detectable change, which describes the change in scores 
that are above the level of measurement error as opposed to the MID (the change that is 
perceived important from the participants’ perspective) (Copay et al., 2007); therefore, these 
estimates do not necessarily reflect a clinically significant difference as concluded. 
 
As the estimated MID values reported in the present study accounted for a small proportion 
of both maximum FSS and MFIS scores, these findings suggest that a small difference in 
fatigue severity/impact is clinically significant in relation to QoL/MS impact. While the 
estimated values for MID accounted for a similar proportion of maximum FSS and MFIS 
scores (6.4-12.6% vs. 4.6-9.7% respectively), MID estimates for the MFIS covered a smaller 
range in scores and values for each individual anchor variable were comparatively lower. 
Therefore, the MFIS may be more responsive to clinically significant changes in fatigue 
when compared to the FSS – perhaps due to the multidimensional nature of the measurement 
scale. However, the MFIS has limited content validity and limited ability to distinguish 
between overall levels of function (e.g. physical, cognitive, and psychosocial function) and 
the impact of fatigue on these domains (Hobart et al., 2013); thus, the smaller MID estimate 
for the MFIS may reflect the stronger association between MFIS and outcome measures of 
global function (e.g. MSIS-29 and EQ-5D) (Flachenecker et al., 2002).  
 
Importantly, the estimates of MID reported in the present study were derived using anchor-
based methods as the participants’ own subjective evaluation of QoL and MS impact were 
used to determine MID. Therefore, these MID estimates reflect the difference in fatigue 
severity/impact that could be interpreted as clinically significant by participants. While 
several cross-sectional studies have reported anchor-based MID estimates for fatigue 
outcome measures in various clinical populations (Nordin et al., 2016), only Rendas-Baum et 
al. (2010) have used the logistic regression methods followed in this study. These methods 
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avoid the need to dichotomise outcomes using arbitrary cut-points in order to determine MID 
by comparing fatigue scores between groups; instead, the transition between categories on 
response items of the EQ-5D/MSIS-29 was used to represent either improving or worsening 
QoL/MS impact. However, due to the cross-sectional study design, the logistic regression 
models used in this study can only predict the changes in fatigue that constitute MID. 
Therefore, future studies should determine whether these MID estimates reflect the level of 
change that participants perceived as meaningful when measuring longitudinal differences in 
fatigue.  
 
As the choice of anchor variable can influence the responsiveness of MID estimates, this 
study used multiple anchor variables from the EQ-5D and MSIS-29 to estimate MID scores 
(Revicki et al., 2008). Therefore, the range of MID scores reported in this study reflect the 
likely effect that differences in fatigue severity/impact would have on the various factors that 
constitute QoL and MS impact. Within this study there was varying responsiveness of 
different anchor variables, as anchor variables related to activity limitations were more 
responsive to changes in FSS and produced lower MID scores in comparison to variables 
related to specific impairments (such as upper/lower limb tremor). Similarly restrictions in 
activities of daily living were most responsive to changes in MFIS, suggesting that a small 
change in fatigue is likely to impact activity limitations in people with MS.  
 
4.1 Limitations 
Due to the cross-sectional design, the MID estimates reported in this study are derived from 
predictive regression models and not from longitudinal differences in fatigue. Therefore, 
there is a need for longitudinal studies to confirm whether the findings of this present study 
can be applied when evaluating differences in fatigue over time. In addition, this study 
reports only anchor-based estimates of MID which limits the ability to compare the results to 
other studies that have used distribution based methods to estimate MID. Importantly, 
although MS diagnosis and type were self-reported, the participant demographics of this 
study sample were representative of a typical MS population (Compston & Coles, 2008; 
Mackenzie et al., 2014), suggesting that the results of this study are generalizable to those 
with MS. However, due to the open online nature of the survey used in this study, all 
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outcomes were self-reported and it was not possible to screen for cognitive impairment which 
may have influenced participant questionnaire responses. Lastly, as this study estimated MID 
using a MS population, these results are not generalizable to other clinical populations in 
which the FSS and MFIS have been validated.  
 
5 Conclusions 
This study provided novel data on the MID of the FSS and MFIS in a large sample of people 
with MS and indicated that a small difference in fatigue severity (FSS = 0.45) and impact 
(MFIS = 4) predicted a significant effect on quality of life. As these estimates were derived 
using the participant’s self-reported MS impact and QoL, the MID values reported in this 
study can be used to inform researchers and clinicians of the clinical significance of 
differences in FSS and MFIS scores. Furthermore, the estimated MID can be used to plan 
adequately powered clinical trials that use the FSS or MFIS as the primary outcome measure 
through informing sample size calculation. However, to confirm the findings of this study, 
future studies should consider using longitudinal designs to provide more precise anchor-
based estimates of MID. 
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Figure legend  
 
Figure 1 MID estimates for the Fatigue Severity Scale and Modified Fatigue Impact Scale, 
and the proportion of maximum FSS/MFIS scores these estimates account for (missing values 





Table 1 Participant demographics 
Participants, n 365 
Age (years), mean ± SD (range) 46.2 ± 11.6 (22-79) 
Time since diagnosis (years), mean ± SD 
(range) 
9.6 ± 8.7 (0-44) 
MS type, % (n) 
 
RRMS 69.3% (253) 
SPMS 18.6% (68) 
PPMS 9.3% (34) 
Benign 0.5% (2) 
Unknown 2.2% (8) 
PDDS, mean ± SD (range) 3.1 ± 2.3 (0-8) 
Sex, % (n) 
 
Female 81.9% (299) 
Male 18.1% (66) 
Work status, % (n) 
 
Working  46.8% (171) 
Not working  53.2% (194) 
Highest level of education, % (n) 
 
University or college  70.4% (257) 
Trade/vocational training  9.9% (36) 
High school 19.5% (71) 
Did not complete high school  0.3% (1) 
FSS, mean ± SD 5.38 ± 1.39 
MFIS (total), mean ± SD 54.5 ±16 
MFIS (physical), mean ± SD 25.3 ± 7.3 
MFIS (cognitive), mean ± SD 23.6 ± 9.2 
MFIS (psychological), mean ± SD 5.4 ± 2 
EQ-5Dindex, mean ± SD 0.51 ± 0.34 
MSIS-29 (physical), mean ± SD 61.5 ± 20.1 
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MSIS-29 (psychological), mean ± SD 27.8 ± 8.9  
Abbreviations : FSS, Fatigue Severity Scale; MFIS, Modified Fatigue Impact 
Scale; MS, Multiple Sclerosis; MSIS-29, Multiple Sclerosis Impact Scale-29; 
PDDS, Patient Determined Disease Steps; PPMS, Primary Progressive Multiple 
Sclerosis; RRMS, Relapsing Remitting Multiple Sclerosis; SPMS, Secondary 






Table 2 Descriptive summary of the 34 potential anchors variables 
EQ-5D/MSIS-29 response items Response categories frequency (%) 
Item mean ± 
SD 
EQ-5D 1 2 3    
1) Mobility 30.7 67.4 1.9   1.7 ± 0.5 
2) Self-care 62.5 32.6 4.9   1.4 ± 0.6 
3) Usual activities 20.0 67.9 12.1   1.9 ± 0.6 
4) Pain/discomfort 24.1 60.0 15.9   1.9 ± 0.6 
5) Anxiety/depression 36.2 52.6 11.2   1.7 ± 0.6 
MSIS-29 1 2 3 4 5  
How much has MS limited your ability to…       
1) ...do physically demanding tasks 5.5 15.6 18.9 33.7 26.3 3.6 ± 1.2 
2) …grip things tightly 19.5 23.0 22.2 23.6 11.8 2.9 ± 1.3 
3) …carry things 15.9 22.5 26.0 21.1 14.5 3.0 ±1.3 
How much have you been bothered by…       
4) …problems with your balance 8.8 17.0 22.2 31.8 20.3 3.4 ± 1.2 
5) …difficulties moving about indoors 20.0 22.2 20.8 23.8 13.2 2.9 ± 1.3 
6) … being clumsy 7.4 24.1 23.3 29.6 15.6 3.2 ± 1.2 
7) …stiffness 11.2 16.7 20.5 30.7 20.8 3.3 ± 1.3 
8) …heavy arms and/or legs 12.1 15.9 21.6 26.6 23.8 3.3 ± 1.3  
9) …tremor of your arms or legs 35.1 24.7 17.5 13.4 9.3 2.4 ± 1.3 
10) …spasms in your limbs 28.8 24.1 18.4 16.2 12.6 2.6 ± 1.4 
11) …your body not doing what you want it to 18.1 22.5 21.9 20.8 16.7 3.0 ± 1.4 
12) …having to depend on others to do things for you 21.1 19.7 18.4 24.1 16.7 3.0 ± 1.4 
13) …limitations in your social and leisure activities at home 10.7 22.5 21.1 25.2 20.5 3.2 ± 1.3 
14) …being stuck at home more than you would like to be 20.0 18.9 12.1 22.2 26.8 3.2 ± 1.5 
15) …difficulties using your hands in everyday tasks 25.8 21.4 21.4 18.1 13.4 2.7 ± 1.4 
16) …having to cut down the amount of time you spend on work or 
other daily activities 
14.0 18.1 20.0 23.6 24.4 3.2 ± 1.4 
17) …problems using transport 34.8 17.8 18.6 14.2 14.5 2.6 ± 1.5 
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18) …taking longer to do things 10.4 15.6 23.0 27.4 23.6 3.4 ± 1.3 
19) …difficulty doing things spontaneously 13.7 14.0 19.5 24.1 28.8 3.4 ± 1.4 
20) …needing to go to the toilet urgently 15.6 15.1 14.0 29.3 26.0 3.4 ± 1.4 
21) …feeling unwell 15.9 23.6 28.5 20.5 11.5 2.9 ± 1.2 
22) …problems sleeping 17.0 15.9 23.3 24.4 19.5 3.1 ± 1.4 
23) …feeling mentally fatigued 5.5 13.4 18.1 37.0 26.0 3.7 ± 1.2 
24) …worries related to your MS 17.0 20.3 25.5 20.3 17.0 3.0 ± 1.3 
25) …feeling anxious or tense 17.5 20.5 21.6 25.2 15.1 3.0 ± 1.3 
26) …feeling irritable, impatient or short tempered 13.4 18.1 23.6 28.2 16.7 3.2 ± 1.3 
27) …problems concentrating 11.8 15.9 27.7 29.9 14.8 3.2 ± 1.2 
28) …lack of confidence 12.6 25.5 21.1 22.2 18.6 3.1 ± 1.3 
29) …feeling depressed 27.4 24.1 19.2 15.1 14.2 2.7 ± 1.4 




Table 3 Variables excluded from MID analysis 
Excluded 
variables  Justification  
  (a) 
 
EQ-5D item 4 Correlation coefficient <0.3 (rs = 0.296, p<0.001)* 
EQ-5D item 5 Correlation coefficient <0.3 (rs = 0.230, p<0.001)* 
MSIS-29 item 2 Violation of proportional odds assumption (χ
2
 = 8.989, p = 0.029)† 
MSIS-29 item 7 Violation of proportional odds assumption (χ
2
 = 12.376, p = 0.006)† 
MSIS-29 item 10 Violation of proportional odds assumption (χ
2
 = 8.013, p = 0.046)† 
MSIS-29 item 24 Correlation coefficient <0.3 (rs = 0.293, p<0.001)* 
MSIS-29 item 25 Violation of proportional odds assumption (χ
2
 = 9.86, p = 0.020)† 
MSIS-29 item 26 Violation of proportional odds assumption (χ
2
 = 17.825, p<0.001)† 
  (b) 
 
EQ-5D item 5 Violation of proportional odds assumption (χ
2
 = 4.992, p = 0.025)† 
MSIS-29 item 19 Violation of proportional odds assumption (χ
2
 = 9.408, p = 0.024)† 
MSIS-29 item 21 Violation of proportional odds assumption (χ
2
 = 11.657, p = 0.009)† 
MSIS-29 item 26 Violation of proportional odds assumption (χ
2
 = 10.151, p = 0.017)† 
MSIS-29 item 27 Violation of proportional odds assumption (χ
2
 = 8.429, p = 0.038)† 
MSIS-29 item 28 Violation of proportional odds assumption (χ
2
 = 12.244, p = 0.007)† 
Abbreviations: MSIS-29, Multiple Sclerosis Impact Scale-29 
(a) variables excluded from Fatigue Severity Scale analysis; (b) variables excluded from Modified 
Fatigue Impact Scale analysis  
* values derived from Spearman correlation analysis  





Supplementary Table 1 Results of the proportional odds models (n=54) which predict the odds of moving between ordinal response categories 





  OR (95% CI) β (SE) Wald χ
2
  p   OR (95% CI) β (SE) Wald χ
2
 p 
EQ-5D item 1 1.657 (1.400-1.962) 0.505 (0.086) 34.4 <0.001 
 
1.052 (1.035-1.068) 0.050 (0.008) 39.8 <0.001 
EQ-5D item 2 1.671 (1.377-2.028) 0.513 (0.099) 27.0 <0.001 
 
1.053 (1.036-1.070) 0.052 (0.008) 39.1 <0.001 
EQ-5D item 3 1.950 (1.634-2.327) 0.668 (0.09) 54.8 <0.001 
 
1.073 (1.055-1.091) 0.070 (0.008) 71.0 <0.001 
EQ-5D item 4 . . . . 
 
1.064 (1.048-1.080) 0.062 (0.008) 65.5 <0.001 
EQ-5D item 5 . . . . 
 
. . . . 
MSIS-29 item 1 2.073 (1.781-2.413) 0.729 (0.077) 88.6 <0.001 
 
1.080 (1.065-1.095) 0.077 (0.007) 116 <0.001 
MSIS-29 item 2 . . . . 
 
1.054 (1.041-1.068) 0.053 (0.007) 66.0 <0.001 
MSIS-29 item 3 1.670 (1.448-1.926) 0.513 (0.073) 49.7 <0.001 
 
1.060 (1.046-1.074) 0.058 (0.007) 78.1 <0.001 
MSIS-29 item 4 1.804 (1.561-2.084) 0.590 (0.074) 64.0 <0.001 
 
1.059 (1.045-1.073) 0.057 (0.007) 76.7 <0.001 
MSIS-29 item 5 1.816 (1.565-2.107) 0.597 (0.076) 61.9 <0.001 
 
1.060 (1.046-1.073) 0.058 (0.007) 75.6 <0.001 
MSIS-29 item 6 1.995 (1.715-2.320) 0.690 (0.077) 80.3 <0.001 
 
1.095 (1.079-1.112) 0.091 (0.008) 143.3 <0.001 
MSIS-29 item 7 . . . . 
 
1.070 (1.056-1.085) 0.068 (0.007) 98.4 <0.001 
MSIS-29 item 8 1.848 (1.597-2.138) 0.614 (0.074) 68.0 <0.001 
 
1.072 (1.057-1.086) 0.069 (0.007) 100.9 <0.001 
MSIS-29 item 9 1.589 (1.368-1.846) 0.463 (0.076) 36.8 <0.001 
 
1.060 (1.045-1.074) 0.058 (0.007) 68.9 <0.001 
MSIS-29 item 10 . . . . 
 
1.055 (1.041-1.069) 0.053 (0.007) 64.1 <0.001 
MSIS-29 item 11 1.760 (1.522-2.036) 0.565 (0.074) 58.0 <0.001 
 
1.070 (1.056-1.085) 0.068 (0.007) 96.0 <0.001 
MSIS-29 item 12 1.934 (1.660-2.254) 0.660 (0.078) 71.4 <0.001 
 
1.068 (1.053-1.082) 0.066 (0.007) 90.2 <0.001 
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MSIS-29 item 13 2.446 (2.077-2.881) 0.894 (0.083) 114.9 <0.001 
 
1.086 (1.070-1.101) 0.082 (0.007) 126.9 <0.001 
MSIS-29 item 14 2.170 (1.848-2.548) 0.775 (0.082) 89.5 <0.001 
 
1.085 (1.069-1.101) 0.082 (0.008) 118.3 <0.001 
MSIS-29 item 15 1.719 (1.482-1.993) 0.542 (0.076) 51.4 <0.001 
 
1.068 (1.053-1.082) 0.065 (0.007) 87.7 <0.001 
MSIS-29 item 16 1.946 (1.677-2.260) 0.666 (0.076) 76.5 <0.001 
 
1.085 (1.069-1.100) 0.081 (0.007) 123.5 <0.001 
MSIS-29 item 17 1.730 (1.481-2.020) 0.548 (0.079) 48.1 <0.001 
 
1.064 (1.049-1.079) 0.062 (0.007) 75.9 <0.001 
MSIS-29 item 18 2.011 (1.731-2.337) 0.699 (0.077) 83.3 <0.001 
 
1.089 (1.073-1.104) 0.085 (0.007) 131.9 <0.001 
MSIS-29 item 19 2.251 (1.921-2.638) 0.811 (0.081) 100.5 <0.001 
 
. . . . 
MSIS-29 item 20 1.759 (1.522-2.032) 0.564 (0.074) 58.5 <0.001 
 
1.060 (1.046-1.074) 0.058 (0.007) 76.3 <0.001 
MSIS-29 item 21 1.855 (1.599-2.152) 0.618 (0.076) 66.7 <0.001 
 
. . . . 
MSIS-29 item 22 1.596 (1.387-1.836) 0.468 (0.072) 42.8 <0.001 
 
1.058 (1.044-1.072) 0.056 (0.007) 73.8 <0.001 
MSIS-29 item 23 2.205 (1.887-2.576) 0.791 (0.079) 99.3 <0.001 
 
1.111 (1.093-1.129) 0.105 (0.008) 164.8 <0.001 
MSIS-29 item 24 . . . . 
 
1.054 (1.041-1.068) 0.053 (0.006) 67.0 <0.001 
MSIS-29 item 25 . . . . 
 
1.067 (1.052-1.081) 0.064 (0.007) 89.7 <0.001 
MSIS-29 item 26 . . . . 
 
. . . . 
MSIS-29 item 27 1.788 (1.547-2.067) 0.581 (0.074) 61.9 <0.001 
 
. . . . 
MSIS-29 item 28 1.641 (1.424-1.889) 0.495 (0.072) 47.2 <0.001 
 
. . . . 
MSIS-29 item 29 1.650 (1.424-1.911) 0.501 (0.075) 44.6 <0.001   1.081 (1.066-1.097) 0.078 (0.007) 109.8 <0.001 
Abbreviations: FSS, Fatigue Severity Scale; MFIS, Modified Fatigue Impact Scale; MSIS-29, Multiple Sclerosis Impact Scale-29 
 
Missing values indicate excluded variables  
        
